Cancer studies and therapeutics最新文献

筛选
英文 中文
The Role of the Nucleotide-Excision Repair (NER) Pathway in Soft Tissue Sarcomas: A Review and a Focus on Its Potential as a Therapeutic Target 核苷-切除修复(NER)通路在软组织肉瘤中的作用:综述及其作为治疗靶点的潜力
Cancer studies and therapeutics Pub Date : 2023-08-18 DOI: 10.31038/cst.2023824
Pillozzi Serena, Scolari Federico, Pasqui Adriano, Boddi Anna, Fancelli Sara, Caliman Enrico, Palchetti Ilaria, Bernini Andrea, Petroni Giulia, Scoccianti Guido, Campanacci Domenico, Antonuzzo Lorenzo
{"title":"The Role of the Nucleotide-Excision Repair (NER) Pathway in Soft Tissue Sarcomas: A Review and a Focus on Its Potential as a Therapeutic Target","authors":"Pillozzi Serena, Scolari Federico, Pasqui Adriano, Boddi Anna, Fancelli Sara, Caliman Enrico, Palchetti Ilaria, Bernini Andrea, Petroni Giulia, Scoccianti Guido, Campanacci Domenico, Antonuzzo Lorenzo","doi":"10.31038/cst.2023824","DOIUrl":"https://doi.org/10.31038/cst.2023824","url":null,"abstract":"Soft tissue sarcomas (STS) are low-incidence, mesenchymal-derived tumors represented by more than 50 his to types. Despite the latest developments, the rates of patients developing recurrent and metastatic disease are high. Many of the mechanisms underlying STS are still unknown","PeriodicalId":72517,"journal":{"name":"Cancer studies and therapeutics","volume":"458 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74286614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Alpha-Fetoprotein-derived Segments as Integrin Peptidomimetics for Potential Cancer Cell Targeting and Therapy: A Review and Commentary 甲胎蛋白衍生片段作为整合素肽模拟物用于潜在的癌细胞靶向和治疗:综述和评论
Cancer studies and therapeutics Pub Date : 2023-08-15 DOI: 10.31038/cst.2023823
G. Mizejewski
{"title":"Alpha-Fetoprotein-derived Segments as Integrin Peptidomimetics for Potential Cancer Cell Targeting and Therapy: A Review and Commentary","authors":"G. Mizejewski","doi":"10.31038/cst.2023823","DOIUrl":"https://doi.org/10.31038/cst.2023823","url":null,"abstract":"Integrins constitute a group of dimeric polypeptide chains that function as natural agonists of cell surface receptor-dependent cell activities.","PeriodicalId":72517,"journal":{"name":"Cancer studies and therapeutics","volume":"60 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72496478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
TRG-High/ATM-Expressed/SIRT1-Absent Profile as Negative Prognostic Marker after Neoadjuvant Chemotherapy for Gastric Cancer trg高/ atm表达/ sirt1缺失作为胃癌新辅助化疗后的阴性预后指标
Cancer studies and therapeutics Pub Date : 2023-08-05 DOI: 10.31038/cst.2023822
{"title":"TRG-High/ATM-Expressed/SIRT1-Absent Profile as Negative Prognostic Marker after Neoadjuvant Chemotherapy for Gastric Cancer","authors":"","doi":"10.31038/cst.2023822","DOIUrl":"https://doi.org/10.31038/cst.2023822","url":null,"abstract":"","PeriodicalId":72517,"journal":{"name":"Cancer studies and therapeutics","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79897588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Significant of Molecular Genotyping Over Serological Phenotyping Techniques in Determination of Blood Group Systems among Multiple Transfused Patients and Blood Donors to Prevent Alloimmunization: A Review Article 分子基因分型比血清学表型分型技术在多次输血患者和献血者血型系统测定中预防同种异体免疫的意义:综述文章
Cancer studies and therapeutics Pub Date : 2023-06-12 DOI: 10.31038/cst.2023821
{"title":"Significant of Molecular Genotyping Over Serological Phenotyping Techniques in Determination of Blood Group Systems among Multiple Transfused Patients and Blood Donors to Prevent Alloimmunization: A Review Article","authors":"","doi":"10.31038/cst.2023821","DOIUrl":"https://doi.org/10.31038/cst.2023821","url":null,"abstract":"","PeriodicalId":72517,"journal":{"name":"Cancer studies and therapeutics","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74100487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Demographic and Clinicopathological Evaluation of Colorectal Adenocarcinoma in Bangladesh at a Tertiary Level Hospital 孟加拉国三级医院结直肠腺癌的人口学和临床病理评估
Cancer studies and therapeutics Pub Date : 2023-01-31 DOI: 10.31038/cst.2023811
{"title":"Demographic and Clinicopathological Evaluation of Colorectal Adenocarcinoma in Bangladesh at a Tertiary Level Hospital","authors":"","doi":"10.31038/cst.2023811","DOIUrl":"https://doi.org/10.31038/cst.2023811","url":null,"abstract":"","PeriodicalId":72517,"journal":{"name":"Cancer studies and therapeutics","volume":"140 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76391425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ambivalent and Conjectural-Synovial Sarcoma 矛盾型和猜想型滑膜肉瘤
Cancer studies and therapeutics Pub Date : 2022-11-18 DOI: 10.31038/cst.2022734
{"title":"Ambivalent and Conjectural-Synovial Sarcoma","authors":"","doi":"10.31038/cst.2022734","DOIUrl":"https://doi.org/10.31038/cst.2022734","url":null,"abstract":"","PeriodicalId":72517,"journal":{"name":"Cancer studies and therapeutics","volume":"33 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88369451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recurrent/Persistent Glioblastoma: Complete Response and 24 Years Disease-free Survival in a 45-Year-Old Female Treated with Antineoplastons (Successful Treatment of Glioblastoma with Antineoplastons) 复发/持续性胶质母细胞瘤:1例45岁女性抗瘤细胞瘤治疗的完全缓解和24年无病生存率(抗瘤细胞瘤治疗成功)
Cancer studies and therapeutics Pub Date : 2022-10-21 DOI: 10.31038/cst.2022733
S. Burzynski, Gregory S. Burzynski, T. Janicki, S. Beenken
{"title":"Recurrent/Persistent Glioblastoma: Complete Response and 24 Years Disease-free Survival in a 45-Year-Old Female Treated with Antineoplastons (Successful Treatment of Glioblastoma with Antineoplastons)","authors":"S. Burzynski, Gregory S. Burzynski, T. Janicki, S. Beenken","doi":"10.31038/cst.2022733","DOIUrl":"https://doi.org/10.31038/cst.2022733","url":null,"abstract":"Rationale: Glioblastoma (GBM), which accounts for 48% of all malignant central nervous system (CNS) tumors and 57% of gliomas, has a very poor prognosis. Patients with recurrent/persistent GBM after standard therapy usually die within six months. The case of an adult female with a recurrent/ persistent GBM is presented here to detail/discuss the efficacy of ANP therapy (Antineoplaston A10 {Atengenal} and Antineoplaston AS2-1 {Astugenal}) in the treatment of this disease. Objectives: This patient was treated at the Burzynski Clinic (BC), as a Compassionate Exemption (CE) according to the Phase II Protocol, BT-20, which utilized ANP therapy in the treatment of patients with GBMs. ANP therapy was delivered via subclavian catheter and infusion pump and then by mouth. Tumor response was measured by sequential magnetic resonance imaging (MRI) of the brain utilizing gadolinium enhancement. Findings: This patient was diagnosed with GBM of the right temporoparietal region in May 1997, at age 45, and underwent two surgical resections, radiation therapy (RT), and gamma knife ablation elsewhere. At age 46 years and eight months, she presented to the BC with recurrent/ persistent disease. She complained of weakness, dizziness, short-term memory loss, and nausea. She had difficulty speaking and walked with assistance due to discoordination and left-sided weakness. Baseline brain MRI at the BC revealed a measurable enhancing nodule in the surgical bed. ANP therapy was initiated in August 1998 and the patient achieved a complete response (CR) within five months. Now, 24 years later, the patient is doing well and showing no evidence of tumor recurrence. Conclusions: The utilization of ANP therapy to obtain a cure in a patient with recurrent/persistent GBM is presented. We conclude that ANP therapy is an attractive therapeutic option for adults with a GBM who are ineligible for or refuse standard therapy or demonstrate recurrent/persistent disease after standard therapy. We present here the successful use of ANP therapy (Antineoplaston A10 {Atengenal} and Antineoplaston AS2-1 {Astugenal}) in the treatment of recurrent/persistent GBM in a 46 year and eight-month-old female, initially diagnosed at age 45 and treated with gross total resection, radiation therapy (RT), gamma knife ablation of recurrent tumor, and subsequent right lobectomy elsewhere. We also present the use of targeted therapy in the treatment of GBM, including our own preliminary results.","PeriodicalId":72517,"journal":{"name":"Cancer studies and therapeutics","volume":"149 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87546666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Continuation of Temozolomide Chemotherapy in a Glioblastoma Patient Post Resolution of COVID-19 Pneumonia 替莫唑胺在COVID-19肺炎消退后胶质母细胞瘤患者的继续化疗
Cancer studies and therapeutics Pub Date : 2022-07-16 DOI: 10.31038/cst.2022732
Anonymous
{"title":"Continuation of Temozolomide Chemotherapy in a Glioblastoma Patient Post Resolution of COVID-19 Pneumonia","authors":"Anonymous","doi":"10.31038/cst.2022732","DOIUrl":"https://doi.org/10.31038/cst.2022732","url":null,"abstract":"","PeriodicalId":72517,"journal":{"name":"Cancer studies and therapeutics","volume":"61 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84639539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Assistance to Patients with Terminal Cancer in the Last 30 Days Prior to Death: Differences in the Care of the Usual Health Care Units and a Palliative Care Unit 临终前30天对晚期癌症患者的帮助:普通保健单位和姑息治疗单位的护理差异
Cancer studies and therapeutics Pub Date : 2022-05-30 DOI: 10.31038/cst.2022731
Renata Carolina Schlögel de Freitas, Renata de Souza-Silva, G. Vigo, L. Oliveira
{"title":"Assistance to Patients with Terminal Cancer in the Last 30 Days Prior to Death: Differences in the Care of the Usual Health Care Units and a Palliative Care Unit","authors":"Renata Carolina Schlögel de Freitas, Renata de Souza-Silva, G. Vigo, L. Oliveira","doi":"10.31038/cst.2022731","DOIUrl":"https://doi.org/10.31038/cst.2022731","url":null,"abstract":"The elaboration of the care plan for patients with terminal cancer must be based on a careful evaluation of clinical, bioethical and prognostic elements. The prognostic assessment can lead to the improvement of treatment strategies and support the planning of care and the efficient use of available resources, helping to minimize the risks of under treatment or excessive and futile treatments, especially in the phase close to death [1]. In the hospital setting, it is common for patients with terminal cancer to receive inadequate and ineffective care, with no provision for palliative care and pain relief. Even in a reality of scarce resources, there is an unnecessary use of invasive and high-tech methods, focused on trying to cure, which are unable to treat the most prevalent symptoms of the disease, prolonging suffering and pain [2].","PeriodicalId":72517,"journal":{"name":"Cancer studies and therapeutics","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73707403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of Alpha Fetoprotein in Hepatocellular Carcinoma 甲胎蛋白在肝细胞癌中的作用
Cancer studies and therapeutics Pub Date : 2022-04-04 DOI: 10.31038/cst.2022723
Short Commentary, Muhammad Waqar Mazhar
{"title":"Role of Alpha Fetoprotein in Hepatocellular Carcinoma","authors":"Short Commentary, Muhammad Waqar Mazhar","doi":"10.31038/cst.2022723","DOIUrl":"https://doi.org/10.31038/cst.2022723","url":null,"abstract":"phosphatase level were high in blood respectively 151 U/L and 493 U/l show in Figure 1. It indicates liver injury and cirrhosis. The AFP test indicates correlation with Hepatocellular carcinoma. The AFP level in patient was 6101 ng/ml and normal values were 0.1 – 10. Higher level of AFP indicates that HCC have positive relation with AFP to proliferate cancer. The test formed by fully automated state of the Art analyzer Beckman Coulter","PeriodicalId":72517,"journal":{"name":"Cancer studies and therapeutics","volume":"155 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86312261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信